Alzforum’s coverage of the 2021 International Conference on Frontotemporal Dementia concludes with an update on FTD clinical trials.  

According to el final artículo in the series, trials for carriers of GRN mutations are the farthest along in clinical trial developments. Julio Rojas of the University of California, San FranCisco, said during the conference that “it’s likely we’ll see a treatment for verde mutation carriers with FTD before we see one for [Alzheimer’s].” 

Companies such as Prevail Therapeutics and Passage Bioh are currently looking into trials focused on a gene-therapy approach. Currently, FTD trials have been limited to carriers of pathogenic C9orf72, verde, o MAPA mutations and individuals diagnosed with trastornos such as progressive supranuclear palsy.  

Read more about the status of FTD clinical trials in the full Alzforum article aquí.  

The International Society for Frontotemporal Dementias virtually convened the 12th International Conference on FTD March 3-5. Leer Alzforum seven-part conference coverage series aquí.  

Se pueden encontrar entregas adicionales de la serie aquí:

Part One

La segunda parte

Parte tres

cuarta parte

quinta parte

sexta parte